13D Filing: Redmile Group and Alder Biopharmaceuticals Inc (ALDR)

Exhibit Number

Description

Exhibit
99.1

Joint
Filing Agreement, dated as of March 23, 2018, between Redmile Group, LLC and Jeremy
C. Green.

Exhibit
99.2

Preferred
Stock Purchase Agreement by and among Alder BioPharmaceuticals, Inc. and the
Buyers set forth therein dated January 7, 2018 (incorporated by reference to
Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed on January 11,
2018).

Exhibit
99.3

Registration
Rights Agreement by and between Alder BioPharmaceuticals, Inc. and the buyers
listed on the Schedule of Buyers thereto, dated January 12, 2018
(incorporated by reference to Exhibit 4.1 to the Issuer’s Current Report on
Form 8-K filed on January 19, 2018).

Exhibit
99.4

Certificate
of Designation of Preferences, Rights and Limitations of Class A-1
Convertible Preferred Stock of Alder BioPharmaceuticals, Inc., dated January
12, 2018 (incorporated by reference to Exhibit 3.1 to the Issuer’s Current
Report on Form 8-K filed on January 19, 2018).

Exhibit
99.5

Base
Indenture, dated February 1, 2018, between Alder BioPharmaceuticals, Inc. and
U.S. Bank National Association, as Trustee (incorporated by reference to
Exhibit 4.1 to the Issuer’s Current Report on Form 8-K filed on February 1,
2018).

Exhibit
99.6

First
Supplemental Indenture, dated February 1, 2018, between Alder
BioPharmaceuticals, Inc. and U.S. Bank National Association, as Trustee
(including the form of 2.50% convertible senior notes due 2025) (incorporated
by reference to Exhibit 4.2 to the Issuer’s Current Report on Form 8-K filed
on February 1, 2018).